Published in Neoplasia on April 01, 2014
Amygdalin influences bladder cancer cell adhesion and invasion in vitro. PLoS One (2014) 0.81
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. Am J Cancer Res (2014) 0.76
Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro. Oncotarget (2016) 0.75
MYC suppresses cancer metastasis by direct transcriptional silencing of αv and β3 integrin subunits. Nat Cell Biol (2012) 2.61
Mechanisms of motility in metastasizing cells. Mol Cancer Res (2010) 2.42
Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer (2007) 2.38
A molecular switch that controls cell spreading and retraction. J Cell Biol (2007) 1.93
Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist (2011) 1.92
Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res (2011) 1.67
Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res (2001) 1.21
Proteomics identification of ITGB3 as a key regulator in reactive oxygen species-induced migration and invasion of colorectal cancer cells. Mol Cell Proteomics (2011) 1.12
Novel agents in renal carcinoma: a reality check. Ther Adv Med Oncol (2012) 1.11
Integrin αvβ3 and fibronectin upregulate Slug in cancer cells to promote clot invasion and metastasis. Cancer Res (2013) 1.10
Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alphav integrins and the participation of MMP2. Int J Cancer (2005) 1.05
The metastasis gene NEDD9 product acts through integrin β3 and Src to promote mesenchymal motility and inhibit amoeboid motility. J Cell Sci (2012) 1.01
Expression profiling reveals genes associated with transendothelial migration of tumor cells: a functional role for alphavbeta3 integrin. Int J Cancer (2007) 0.98
Cellular receptors of extracellular matrix molecules. Curr Pharm Des (2009) 0.98
Protective effects of the mTOR inhibitor everolimus on cytoskeletal injury in human podocytes are mediated by RhoA signaling. PLoS One (2013) 0.98
Role of adhesion receptor trafficking in 3D cell migration. Curr Opin Cell Biol (2013) 0.97
CXCR4 chemokine receptor engagement modifies integrin dependent adhesion of renal carcinoma cells. Exp Cell Res (2007) 0.96
The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line. Cancer Lett (2011) 0.95
Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells. Cancer Lett (2012) 0.95
Cytokeratin 18 expression pattern correlates with renal cell carcinoma progression: relationship with Snail. Int J Oncol (2010) 0.89
Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2. Br J Cancer (2013) 0.89
Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development. Curr Clin Pharmacol (2011) 0.89
Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells. Br J Cancer (2012) 0.87
Down-regulation of β3-integrin inhibits bone metastasis of small cell lung cancer. Mol Biol Rep (2011) 0.81
Transient down-regulation of beta1 integrin subtypes on kidney carcinoma cells is induced by mechanical contact with endothelial cell membranes. J Cell Mol Med (2007) 0.80
Akt and RhoA inhibition promotes anoikis of aggregated B16F10 melanoma cells. Cell Biol Int (2012) 0.80
Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo. PLoS One (2013) 1.02
The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line. Cancer Lett (2011) 0.95
Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells. Cancer Lett (2012) 0.95
Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells. J Cell Mol Med (2014) 0.83
Publication of original research in urologic journals--a neglected orphan? PLoS One (2012) 0.81
Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib. J Cell Mol Med (2014) 0.81
Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells. J Cell Mol Med (2015) 0.79
Use of complementary and alternative medicine before and after organ removal due to urologic cancer. Patient Prefer Adherence (2015) 0.77
I publish in I edit?--Do editorial board members of urologic journals preferentially publish their own scientific work? PLoS One (2013) 0.75
Globalization in Urology: A Bibliographical Analysis of Cross-Continent Publication between 2002 and 2012. Urol Int (2015) 0.75